Miami man pleads guilty to selling adulterated, misbranded HIV drugs across U.S.

Miami man pleads guilty to selling adulterated, misbranded HIV drugs across U.S.


A Miami man has pleaded guilty in federal court to distributing adulterated HIV drugs dispensed to U.S. patients.

Miami Herald | Tribune News Service | Getty Images

A Miami man pleaded guilty to distributing as much as $25 million worth of misbranded and adulterated HIV drugs that were dispensed by pharmacies across the U.S. to unsuspecting patients, federal prosecutors said.

Armando Herrera, 43, faces a maximum possible sentence of five years in prison for the crime.

Herrera pleaded guilty in U.S. District Court in Miami on Monday to one count of conspiracy to introduce adulterated and misbranded drugs in the U.S. market, court filings show.

A medication is adulterated if a substance has been substituted for the drug in whole or in part.

Herrera and his co-conspirators set up companies in Texas, California and Washington state that acquired large quantities of misbranded and adulterated HIV medication from legal channels, falsified the pills’ packaging and sold them at a steep discount to wholesalers that later sold them to pharmacies, court documents say.

Prosecutors said the wholesalers were involved in the criminal scheme, but the pharmacies were unaware that the drugs were altered or misbranded.

The adulterated and misbranded drugs included Truvada, Biktarvy and other unnamed medications.

Truvada is prescribed to prevent HIV infection in people who are at risk of contracting the virus. The medication is also used in combination with other drugs to treat infection.

Biktarvy is prescribed to treat HIV infection. Truvada and Biktarvy are manufactured by Gilead Sciences.

Herrera and his co-conspirators received between $16.7 million and $25 million in payment from two wholesalers, according to court filings.

The filings did not say how Herrera and his co-conspirators acquired the drugs.

Medications are often siphoned off the legal market by purchasing them from individual patients who were prescribed the drugs.

Herrera is scheduled to be sentenced Dec. 21. His lawyer did not immediately respond to CNBC’s request for comment.



Source

Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale
Health

Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale

Jim Cramer says don’t sweat Novo Nordisk’s head start over Club holding Eli Lilly in the obesity pill market. Eli Lilly stock slipped about half a percent this morning, while Novo Nordisk shares surged more than 8% after becoming the first to secure FDA approval for a GLP-1 weight-loss pill. “[Novo] got approval ahead of […]

Read More
FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk
Health

FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk

The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, Nov. 24, 2025. Tom Little | Reuters The U.S. Food and Drug Administration on Monday approved the first-ever GLP-1 pill for obesity from Wegovy maker Novo Nordisk, a landmark decision that health experts […]

Read More
UnitedHealth Group commits to improvements after independent audit, patient backlash
Health

UnitedHealth Group commits to improvements after independent audit, patient backlash

UnitedHealthcare sign is displayed at its office building in Minnetonka, Minnesota, U.S., Dec. 11, 2025. Tim Evans | Reuters UnitedHealth Group on Friday released the first results from a sprawling independent audit of its business practices and committed to a wide range of steps to track and implement improvements in three specific areas. The health-care […]

Read More